Actionable Stock Market Trading Newswire. Built for Traders, by Traders.
All news is property of their respective owners.

Citigroup Maintains Buy on Zymeworks, Lowers Price Target to $27

Citigroup analyst Yigal Nochomovitz maintains Zymeworks (NYSE:ZYME) with a Buy and lowers the price target from $28 to $27.

byBenzinga Newsdesk

August 29, 2022

1 minute read

Citigroup analyst Yigal Nochomovitz maintains Zymeworks (NYSE:ZYME) with a Buy and lowers the price target from $28 to $27.

Barclays Maintains Overweight on Twist Bioscience, Raises Price Target to $45

By Benzinga Newsdesk

July 13, 7:10 AM

Barclays analyst Luke Sergott maintains Twist Bioscience (NASDAQ:TWST) with a Overweight and raises the price target from $40 to $45.

TWST

Elon Musk Will Return Twitter To Public Ownership In About 3 Years After Takeover: Report

By Rachit Vats

May 3, 8:50 PM

Tesla Inc (NASDAQ: TSLA) CEO Elon Musk has told potential investors he plans to return Twitter Inc (NYSE: TWTR) to public ownership in as little as thr

TSLA

News

JetBlue To Fly Nonstop Between New York’s JFK And London Gatwick Airport

By Akanksha

September 30, 8:18 AM

JetBlue Airways Corp (NASDAQ:JBLU) has expanded its presence in the transatlantic market with a new, nonstop service between New York’s John…

JBLU

Recursion Pharmaceuticals Q4 EPS $(0.31) Up From $(0.38) YoY, Sales $13.68M Up From $2.53M YoY

By Michael Horton

February 27, 5:38 PM

Recursion Pharmaceuticals (NASDAQ:RXRX) reported quarterly losses of $(0.31) per share. This is a 18.42 percent increase over losses of $(0.38) per share from the same period last year. The company reported $13.68

RXRX

Citigroup Maintains Buy on Zymeworks, Lowers Price Target to $27

Related Posts

Barclays Maintains Overweight on Twist Bioscience, Raises Price Target to $45

Elon Musk Will Return Twitter To Public Ownership In About 3 Years After Takeover: Report

JetBlue To Fly Nonstop Between New York’s JFK And London Gatwick Airport

Recursion Pharmaceuticals Q4 EPS $(0.31) Up From $(0.38) YoY, Sales $13.68M Up From $2.53M YoY